Cantor Fitzgerald Has Weak Forecast for AXSM FY2026 Earnings

Key Points

• Cantor Fitzgerald has lowered its FY2026 earnings per share (EPS) estimates for Axsome Therapeutics from ($2.27) to ($2.54), indicating a more negative outlook.
• Despite the downgrade, other analysts have given Axsome a "buy" rating, with price targets ranging from $150.00 to $190.00.
• Insider trading has seen significant activity, with key executives selling shares, including COO Mark L. Jacobson and CEO Herriot Tabuteau, raising concerns about their confidence in the company's prospects.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities researchers at Cantor Fitzgerald reduced their FY2026 EPS estimates for shares of Axsome Therapeutics in a research report issued on Tuesday, September 16th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($2.54) for the year, down from their prior forecast of ($2.27). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.08. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. The company had revenue of $150.04 million during the quarter, compared to analysts' expectations of $140.02 million.

A number of other research analysts have also issued reports on AXSM. Wells Fargo & Company upgraded shares of Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, June 10th. Oppenheimer assumed coverage on shares of Axsome Therapeutics in a report on Tuesday, June 3rd. They issued an "outperform" rating and a $185.00 price objective on the stock. Bank of America upped their price objective on shares of Axsome Therapeutics from $173.00 to $176.00 and gave the company a "buy" rating in a report on Tuesday, August 5th. Finally, Morgan Stanley started coverage on shares of Axsome Therapeutics in a report on Thursday, July 3rd. They set an "overweight" rating and a $190.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating and thirteen have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $177.86.

Axsome Therapeutics Stock Up 0.9%

Shares of NASDAQ AXSM traded up $1.08 during trading hours on Thursday, hitting $117.03. 215,801 shares of the stock were exchanged, compared to its average volume of 750,502. The company has a quick ratio of 1.51, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. The company has a market cap of $5.84 billion, a PE ratio of -23.09 and a beta of 0.54. The firm has a fifty day moving average price of $112.88 and a 200-day moving average price of $110.24. Axsome Therapeutics has a 12 month low of $75.56 and a 12 month high of $139.13.

Insider Buying and Selling

In other Axsome Therapeutics news, Director Mark E. Saad sold 9,127 shares of the business's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $125.07, for a total value of $1,141,513.89. Following the transaction, the director directly owned 10,002 shares of the company's stock, valued at approximately $1,250,950.14. The trade was a 47.71% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Herriot Tabuteau sold 27,907 shares of the business's stock in a transaction on Friday, September 12th. The shares were sold at an average price of $118.96, for a total transaction of $3,319,816.72. Following the completion of the transaction, the chief executive officer directly owned 7,229 shares in the company, valued at $859,961.84. This represents a 79.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 187,948 shares of company stock worth $22,247,086 in the last ninety days. Insiders own 22.30% of the company's stock.

Hedge Funds Weigh In On Axsome Therapeutics

Several institutional investors have recently bought and sold shares of AXSM. BVF Inc. IL grew its stake in shares of Axsome Therapeutics by 21.8% during the 1st quarter. BVF Inc. IL now owns 1,690,221 shares of the company's stock worth $197,130,000 after purchasing an additional 302,157 shares during the period. Geode Capital Management LLC grew its stake in shares of Axsome Therapeutics by 5.8% during the 2nd quarter. Geode Capital Management LLC now owns 989,453 shares of the company's stock worth $103,303,000 after purchasing an additional 54,600 shares during the period. State Street Corp grew its stake in shares of Axsome Therapeutics by 5.8% during the 2nd quarter. State Street Corp now owns 958,503 shares of the company's stock worth $100,058,000 after purchasing an additional 52,483 shares during the period. Invesco Ltd. grew its stake in shares of Axsome Therapeutics by 23.8% during the 1st quarter. Invesco Ltd. now owns 857,001 shares of the company's stock worth $99,952,000 after purchasing an additional 164,537 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of Axsome Therapeutics by 41.1% during the 2nd quarter. Bank of America Corp DE now owns 753,429 shares of the company's stock worth $78,650,000 after purchasing an additional 219,527 shares during the period. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.